Biogen Inc. has disclosed huntingtin (HTT; HD) (mutant) splicing modulators reported to be useful for the treatment of Huntington’s disease and spinal muscular atrophy (SMA).
Nanjing Mingde New Drug Research Co. Ltd. has described potassium voltage-gated channel subfamily KQT member 2/3 (KCNQ2/3) activators reported to be useful for the treatment of epilepsy.
Breakpoint Therapeutics GmbH has divulged Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.
Rubedo Life Sciences Inc. has identified Bcl-2-like protein 1 (Bcl-xl; Bcl-X; BCL2L1) inhibitors acting as senolytic agents reported to be useful for the treatment of autoimmune disease, cancer, cardiovascular disorders, cognitive disorders, diabetes, inflammatory, metabolic and neurological disorders, among others.
Dana-Farber Cancer Institute Inc. has synthesized tyrosine-protein phosphatase non-receptor type 6 (PTPN6; PTP-1C; SH-PTP1) activators reported to be useful for the treatment of autoimmune disease and cancer.
In what represents the company’s first filing, the co-founders of Pharmalytix Inc., Sierra Houang and Lee Grady, describe their creation of a simple, quick, low-cost at home lateral flow test for determining insulin quality.
Betta Pharmaceuticals Co. Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising a VHL-binding agent coupled to a GTPase KRAS-targeting moiety through a linker acting as KRAS degradation inducers reported to be useful for the treatment of cancer.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has divulged compounds acting as apolipoprotein A (ApoA; LPA) inhibitors reported to be useful for the treatment of hyperlipidemia, coronary heart disease, ischemic stroke and myocardial infarction.
Shanghai Tyk Medicines Co. Ltd. and Tyk Medicines Inc. have identified poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.
RSS
